Skip navigation

Regulatory Updates | Data Anonymisation | Policy 0070 | Patients as Partners | Publication Strategy

June 12-13, 2019
  • Amsterdam, The Netherlands

With the EMA moving to Amsterdam in early 2019, there are still a lot of questions in the pharmaceutical industry surrounding what EMA’s highest priorities are and when Phase II of Policy 0070 will be implemented. It is never more critical than now to gather with your colleagues from clinical trial transparency, data management, publications and medical writing to exchange proven best practices and better understand how your peers are preparing to comply with changing regulations.

Join CBI’s 8th Annual Publication and Clinical Trial Transparency conference to participate in a knowledge exchange and gain insight on EMA’s strategic priorities, benchmark industry trends in clinical trial transparency and establish timelines and best practices for publication planning in accordance with ICMJE and GPP3 guidelines.

Expert Presentation Topics Include:

  • Share updates to Policy 0070 implementation standards across industry
  • Identify the synergies between publishing lay summaries and publications
  • Benchmark data sharing practices and learn about TAG group initiatives
  • Discuss how to implement a mentality of patients as collaborators to gain more patient insight to clinical trial disclosures
  • Evaluate the intended purpose and reality of publishers guidelines
  • Build a knowledge center for understanding global transparency requirements and communicating them to your teams
  • Analyze how the EU GDPR has effected transparency policies across European pharmaceutical companies
  • Connect publications timelines with disclosure priorities for a more effective results sharing process

Previous Attendee Acclaim:

Informative and necessary congress.

Trial Transparency Manager, Sanofi

Well-organized conference allowing a lot of interactions
in between participants and between participants,
speakers, and sponsors.

Senior Medical Writer, Swedish Orphan Biovitrum

A good forum to share progress in the different but interconnected fields!

Anonymous

Informative congress and necessary with an ever-evolving regulatory landscape that impacts publications
and medical communication.

Medical Writer, Envision Pharma Group

Very comprehensive and followed a good flow.

Senior Medical Writer, Kinapse

Great Networking event, very open people.

Medical Writer, Boehringer Ingelheim Pharma GmbH

8th Annual Publication and Clinical Trial Transparency Europe

Regulatory Updates | Data Anonymisation | Policy 0070 | Patients as Partners | Publication Strategy

With the EMA moving to Amsterdam in early 2019, there are still a lot of questions in the pharmaceutical industry surrounding what EMA’s highest priorities are and when Phase II of Policy 0070 will be implemented. It is never more critical than now to gather with your colleagues from clinical trial transparency, data management, publications and medical writing to exchange proven best practices and better understand how your peers are preparing to comply with changing regulations.

Join CBI’s 8th Annual Publication and Clinical Trial Transparency conference to participate in a knowledge exchange and gain insight on EMA’s strategic priorities, benchmark industry trends in clinical trial transparency and establish timelines and best practices for publication planning in accordance with ICMJE and GPP3 guidelines.

Expert Presentation Topics Include:

  • Share updates to Policy 0070 implementation standards across industry
  • Identify the synergies between publishing lay summaries and publications
  • Benchmark data sharing practices and learn about TAG group initiatives
  • Discuss how to implement a mentality of patients as collaborators to gain more patient insight to clinical trial disclosures
  • Evaluate the intended purpose and reality of publishers guidelines
  • Build a knowledge center for understanding global transparency requirements and communicating them to your teams
  • Analyze how the EU GDPR has effected transparency policies across European pharmaceutical companies
  • Connect publications timelines with disclosure priorities for a more effective results sharing process

Previous Attendee Acclaim:

Informative and necessary congress.

Trial Transparency Manager, Sanofi

Well-organized conference allowing a lot of interactions
in between participants and between participants,
speakers, and sponsors.

Senior Medical Writer, Swedish Orphan Biovitrum

A good forum to share progress in the different but interconnected fields!

Anonymous

Informative congress and necessary with an ever-evolving regulatory landscape that impacts publications
and medical communication.

Medical Writer, Envision Pharma Group

Very comprehensive and followed a good flow.

Senior Medical Writer, Kinapse

Great Networking event, very open people.

Medical Writer, Boehringer Ingelheim Pharma GmbH